Press Release

« Back

Ovid Therapeutics to Present at Two Upcoming Investor Conferences

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that members of the company’s management team will present at two upcoming investor conferences:

  • Cowen & Company 38th Annual Health Care Conference
    Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid, will present a corporate overview on Monday, March 12, 2018 at 2:10 p.m. ET. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, MA.
  • BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
    Yaron Werber, M.D., chief business and financial officer of Ovid, will present a corporate overview on Friday, March 23, 2018 at 10:00 a.m. ET. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York, NY.

Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at Archived replays of the webcasts will be available on the company's website for two weeks following each live presentation.

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.

For more information on Ovid, please visit

Ovid Contacts:
Burns McClellan
Steve Klass, 212-213-0006

Pure Communications, Inc.
Katie Engleman, 910-509-3977

Primary Logo

Ovid Therapeutics Inc.